BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8814378)

  • 1. Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
    Mahendra P; Hood IM; Lee MA; Mewar D; Bass G; Flower CD; Wilson CB; Marcus RE
    Clin Oncol (R Coll Radiol); 1996; 8(3):198-200. PubMed ID: 8814378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
    Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
    Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
    Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
    Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature.
    Mileshkin L; Prince HM; Rischin D; Zimet A
    Bone Marrow Transplant; 2001 Mar; 27(5):559-63. PubMed ID: 11313694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer.
    Vahdat L; Raptis G; Fennelly D; Hamilton N; Reich L; Tiersten A; Harrison M; Hudis C; Moore M; Yao TJ; Norton L; Crown J
    Clin Cancer Res; 1995 Nov; 1(11):1267-73. PubMed ID: 9815921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial pneumonitis as a late complication of high dose therapy with cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
    Lin AY; Flower CM; Chen MC; Johnson JR; Justice RL
    Clin Oncol (R Coll Radiol); 1998; 10(1):65. PubMed ID: 9543620
    [No Abstract]   [Full Text] [Related]  

  • 7. High dose mitoxantrone with thiotepa, cyclophosphamide and autologous stem cell rescue for high risk stage II and stage III breast cancer. German GABG-4/EH-93-Study.
    Zander AR; Krüger W; Kröger N; Damon L; Königmann M; Berdel WE; Gieseking F; Schäfer-Eckart K; Möbus V; Frickhofen N; Wandt H; Illiger HJ; Metzner B; Kolbe K; Wörmann B; Trümper L; Huber C; Hossfeld DK; Maass H; Jonat W
    Bone Marrow Transplant; 1996 Sep; 18 Suppl 1():S24-5. PubMed ID: 8899165
    [No Abstract]   [Full Text] [Related]  

  • 8. Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer.
    Bitran JD; Samuels B; Klein L; Hanauer S; Johnson L; Martinec J; Harris E; Kempler J; White W
    Bone Marrow Transplant; 1996 Feb; 17(2):157-62. PubMed ID: 8640160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose cyclophosphamide, carboplatin, and etoposide with autologous stem cell rescue in patients with breast cancer.
    deMagalhaes-Silverman M; Rybka WB; Lembersky B; Bloom EJ; Lister J; Pincus SM; Voloshin M; Wilson J; Ball ED
    Am J Clin Oncol; 1996 Apr; 19(2):169-73. PubMed ID: 8610643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose chemotherapy with autologous stem cell support for breast cancer: a review of the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Ayash LJ; Elias A; Wheeler C; Tepler I; Schwartz G; Schnipper L; Frei E; Antman K
    J Hematother; 1993; 2(4):507-11. PubMed ID: 7916250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer.
    Rodenhuis S; Bontenbal M; Beex LV; Wagstaff J; Richel DJ; Nooij MA; Voest EE; Hupperets P; van Tinteren H; Peterse HL; TenVergert EM; de Vries EG;
    N Engl J Med; 2003 Jul; 349(1):7-16. PubMed ID: 12840087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [High-dosage chemotherapy and the autologous transplantation of peripheral hematopoietic progenitor cells in breast cancer: the initial results, analysis of toxicity and the necessary support means].
    Sola Rocabert C; Mesía R; Mendoza L; Tabernero JM; Amill B; Maroto P; Bellet M; Ojeda B; Alonso MC; Verger G
    Med Clin (Barc); 1995 Oct; 105(11):407-11. PubMed ID: 7475451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
    Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
    Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A feasibility study of multiple cycle therapy with melphalan, thiotepa, and paclitaxel followed by mitoxantrone, thiotepa, and paclitaxel with autologous hematopoietic cell support for metastatic breast cancer.
    Hu WW; Long GD; Stockerl-Goldstein KE; Johnston LJ; Chao NJ; Negrin RS; Blume KG
    Clin Cancer Res; 1999 Nov; 5(11):3411-8. PubMed ID: 10589752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group.
    Stadtmauer EA; O'Neill A; Goldstein LJ; Crilley PA; Mangan KF; Ingle JN; Brodsky I; Martino S; Lazarus HM; Erban JK; Sickles C; Glick JH
    N Engl J Med; 2000 Apr; 342(15):1069-76. PubMed ID: 10760307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy (CTM) for breast cancer.
    Damon LE; Wolf JL; Rugo HS; Gold E; Zander AR; Cassidy M; Cecchi G; Cohen N; Irwin D; Tracy M; Ries CA; Linker CA
    Bone Marrow Transplant; 2000 Aug; 26(3):257-68. PubMed ID: 10967563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive cycles of cyclophosphamide, thiotepa, and carboplatin intensification with peripheral-blood progenitor cells and filgrastim in advanced breast cancer patients.
    Shapiro CL; Ayash L; Webb IJ; Gelman R; Keating J; Williams L; Demetri G; Clark P; Elias A; Duggan D; Hayes D; Hurd D; Henderson IC
    J Clin Oncol; 1997 Feb; 15(2):674-83. PubMed ID: 9053493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose chemotherapy consolidation with autologous stem cell rescue in metastatic breast cancer: a 10-year experience.
    Laport GF; Grad G; Grinblatt DL; Bitran JD; Williams SF
    Bone Marrow Transplant; 1998 Jan; 21(2):127-32. PubMed ID: 9489628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous stem cell support followed by posttransplantation doxorubicin as initial therapy for metastatic breast cancer.
    deMagalhaes-Silverman M; Bloom E; Lembersky B; Lister J; Pincus S; Rybka W; Voloshin M; Wilson J; Ball E
    Clin Cancer Res; 1997 Feb; 3(2):193-7. PubMed ID: 9815672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
    Morabito F; Irrera G; Oliva E; Console G; Martino M; Pucci G; Messina G; Barbaro P; Palazzo S; Iacopino P
    Bone Marrow Transplant; 2001 Nov; 28(9):883-8. PubMed ID: 11781650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.